Clearmind Medicine (CSE: CMND), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, today announced that it will host Psychedelics for Alcoholism. The live virtual event highlights new potential treatments for alcohol use disorder and binge drinking. Registration is open and free to all for the online event, which is slated to start at 12 p.m. ET/9 a.m. PT on Oct. 20, 2021. The event will feature brief speaker presentations followed by a discussion with a question-and-answer session. The company has curated a panel of scientists, thought leaders, therapists and pundits to share insight on the mounting evidence suggesting the effectiveness of psychedelics, and specifically MEAI, in the regulation of excessive drinking. Clearmind representatives will also provide an update on the company’s MEAI-based medicines and their potential for the treatment of alcohol use disorder and binge drinking. “We ’re in the middle of a psychedelic renaissance that is revolutionizing the way we treat mental disorders,” said Adi Zuloff-Shani, Ph.D., CEO of Clearmind. “We put this event together to increase awareness of the advances being made in the field, and more specifically generate awareness of the work Clearmind is doing with regard to alcohol use and binge drinking.”
To view the full press release, visit https://ibn.fm/4jFaW
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. The company’s intellectual portfolio currently consists of two patent families. The first, “Binge Behavior Regulators,” has been granted in the U.S., Europe, China and India, with pending divisional applications in Europe and the U.S. The second, “Alcohol Beverage Substitute,” has been approved for a European patent, with pending applications in the U.S., China and India. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio. Shares of Clearmind are listed for trading on the Canadian Securities Exchange under the symbol CMND and the Frankfurt Stock Exchange under the symbol CWY0. For more information about the company, visit www.ClearmindMedicine.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork
